Results from a phase 2 trial found a drug-vaccine combination developed by Merck and Moderna cut the risk of recurrence or death in patients with severe melanomas by 49%.The experimental therapy involves an mRNA vaccine from Moderna in combination with Merck's cancer drug Keytruda. Patients with resected stage 3 or 4 melanoma who received the combination therapy were 49% less likely to die or have their cancer return within three years, compared to those who received only Keytruda.The findings build on results from an earlier phase study that followed patients for two years, the drugmakers said in a Dec.

第二阶段试验的结果发现，默克公司和摩德纳公司开发的药物-疫苗组合将严重黑色素瘤患者的复发或死亡风险降低了49%。实验疗法涉及来自Moderna的mRNA疫苗与默克公司的抗癌药物Keytruda联合使用。与仅接受Keytruda治疗的患者相比，接受联合治疗的切除3或4期黑色素瘤患者在三年内死亡或复发的可能性降低了49%。制药商在12月1日表示，这些发现是基于对患者进行为期两年的早期研究结果得出的。

14 news release. 'We've now answered the one remaining scientific question: Is this benefit short-lived or is it going to be durable?' Moderna President Stephen Hoge, MD, told Bloomberg. Moderna and Merck started a phase 3 trial in July. Dr. Hoge told Bloomberg the trial could take up to four years to confirm earlier stage results, though federal regulators could move to make the treatment available to some patients sooner. .

14新闻稿。“我们现在已经回答了剩下的一个科学问题：这种益处是短暂的还是持久的？”Moderna总裁、医学博士斯蒂芬·霍格（StephenHoge）告诉彭博社。Moderna和默克公司于7月开始了第三阶段试验。霍格博士告诉彭博社，这项试验可能需要长达四年的时间才能确认早期结果，尽管联邦监管机构可能会采取行动，让一些患者更快地接受治疗。。